-
Shanghai Pharmaceuticals Rosuvastatin Calcium Tablets Approved for Production
Time of Update: 2021-08-12
On the 17th, Shanghai Pharmaceuticals issued an announcement stating that rosuvastatin calcium tablets of Shanghai Pharmaceutical Xinyi, a wholly-owned subsidiary of Shanghai Pharmaceuticals, received the "Drug Registration Certificate" issued by the State Food and Drug Administration, and the drug was approved for production .
-
AstraZeneca Olapali Tablets New Indication Approved for Treatment of Prostate Cancer in China
Time of Update: 2021-08-12
Among mCRPC patients with BRCA1/2 or ATM gene mutations (subgroups of HRR gene mutations), olaparib and abiraterone or enza Compared with Lutamide, the overall survival (OS) of the patient was significantly improved, reaching the key secondary endpoint of the trial .
-
Atopic dermatitis new drug CCR4 inhibitor phase Ib results positive company share price doubles
Time of Update: 2021-08-12
Compared with placebo, the RPT193 group showed significant improvement in key efficacy indicators at the end of the 4-week treatment, including the eczema area and severity index (EASI) score, the validated investigator's overall assessment (vIGA) and the pruritus score (NRS) Improvement .
-
Osaikang's daptomycin for injection obtained the drug registration certificate
Time of Update: 2021-08-12
China approved the import of this species in 2009 for the treatment of bloodstream infections (bacteremia) caused by Staphylococcus aureus (including methicillin-sensitive and methicillin-resistant) associated with infective endocarditis on the right side In 2013, new indications for bloodstream infections, skin infections and soft tissue infections were approved .
-
Tetrabenazine officially approved in China for the treatment of Huntington's disease
Time of Update: 2021-08-12
1 category of imported new drug tetrabenazine tablets declared by Shandong Bausch & Lomb Freda Pharmaceuticals has been approved .
Screenshot source: NMPA official websitePublic information shows that tetrabenazine is the first drug approved in the United States for the treatment of Huntington's disease .
-
The State Food and Drug Administration requests revision of the instructions for Carbimazole Tablets
Time of Update: 2021-08-12
Medical Network News on June 22, the State Food and Drug Administration issued an announcement stating that according to the results of the adverse drug reaction assessment, it was decided to make unified revisions to the instructions of carbimazole tablets [adverse reactions] [taboos] [precautions] and other items .
-
Prepare for 2021 medical insurance negotiations! The price of PCSK9 monoclonal antibody is reduced by 47%
Time of Update: 2021-08-12
for the active price reduction of the PCSK9 monoclonal antibody aliximab product in Liaoning Province, and the online price was reduced from 1888 yuan The adjustment to 998 yuan will be implemented from June 18th .
-
Servier mutant IDH1/2 enzyme dual inhibitor vorasidenib shows efficacy
Time of Update: 2021-08-12
Servier recently announced that the results of a phase 1 dose-escalation clinical study (NCT02481154) evaluating vorasidenib as a single agent for the treatment of isocitrate dehydrogenase (IDH) mutant advanced solid tumors (including low-grade gliomas, LGG) have been published In the famous international cancer research journal "Clinical Cancer Research" .
-
2021 Chinese hospital bed scale top 100 list released
Time of Update: 2021-08-12
The "Medical Circle" media has launched the "ranking list of hospital beds in China" for many years, giving the industry a glimpse of the large-scale development of large hospitals .
-
FDA approves Brexafemme, the first new class of antifungal drug, Hausen owns Chinese rights
Time of Update: 2021-08-12
Recently, Synexis, a partner of Hausen Pharmaceuticals, announced that the US Food and Drug Administration has approved a new broad-spectrum antifungal drug Brexafemme, which is an oral drug for the treatment of female patients with vulvovaginal candidiasis .
-
Eli Lilly's IL-17A inhibitor Taltz is approved by NICE in the UK for the treatment of axial spondyloarthritis
Time of Update: 2021-08-12
CompilenewbornThe National Institute of Health and Clinical Excellence (NICE) recently released a final assessment document (FAD) recommending Eli Lilly’s anti-inflammatory drug Taltz (ixekizumab) for the treatment of active axial spondyloarthritis (axSpA) .
-
Pharmaceutical companies sued the State Food and Drug Administration to win!
Time of Update: 2021-08-12
The original review decision made an error in citing the "Regulations on the Administration of Drug Technology Transfer Registration", and the reason for not approving the supplementary application for the drug involved in the case was untenable .
-
Another blockbuster product of new oncolytic virus drug approved!
Time of Update: 2021-08-12
In October 2020, Replimune announced the clinical trial data of RP1 single agent or/and nivolumab in the treatment of skin cancer at the SITC2020 annual meeting: including skin cancer patients resistant to PD-1 and squamous cell carcinoma (CSCC) In patients, the combination therapy of RP1 and nivolumab showed positive anti-tumor activity; in CSCC patients (N=11), the objective response rate (ORR) was 72.
-
Hutchison Medicine announces that Sofatinib is approved for the treatment of advanced pancreatic neuroendocrine tumors
Time of Update: 2021-08-11
Hutchison Pharmaceuticals (Nasdaq/London Stock Exchange: HCM) today announced that Sofatinib has been officially approved by the China National Medical Products Administration ("SFDA") for the treatment of advanced pancreatic neuroendocrine tumors (pNETs) .
The median PFS for patients in the sofatinib treatment group was 10.
-
China Resources Double Crane: Subsidiary Linezolid Tablets Obtained Drug Registration Certificate
Time of Update: 2021-08-11
The original linezolid tablets were developed by Pfizer Pharmaceuticals in the United States.
According to the global drug sales database of 71 countries, in 2020, the global sales of linezolid tablets will be 278 million US dollars .
-
Hausen Pharmaceutical's Class 1 new drug was approved to be marketed for the treatment of chronic hepatitis B
Time of Update: 2021-08-11
On the evening of June 22, China’s National Food and Drug Administration (NMPA) recently announced that Haosen Pharmaceutical’s Class 1 new drug imitenofovir tablets (also known as eimofolamine tenofovir tablets) has officially been approved in China.
Screenshot source: NMPA official website
-
Chinese wolfberry exports to the EU to break barriers and make new breakthroughs
Time of Update: 2021-08-11
(Finish) Medical Network, June 24, a reporter learned from Yinchuan Customs on the 23rd that the European Commission recently announced the lifting of the stricter inspection measures on the 20% entry inspection rate of Chinese goji berries exported to the EU, which means that Chinese goji berries will resume normal exports to the EU.
-
Baiyunshan: Cefuroxime sodium for injection passed the consistency evaluation of generic drugs
Time of Update: 2021-08-11
On June 22, Baiyunshan announced that its subsidiary Tianxin Pharmaceutical's cefuroxime sodium for injection has passed the consistency evaluation of generic drugs .
According to public information, the domestic manufacturers of cefuroxime sodium for injection that have passed or deemed to have passed the consistency evaluation include Zhejiang Huidisen Pharmaceutical Co.
-
Deepen the reform of the medical and health system and use Chinese-style methods to solve global problems
Time of Update: 2021-08-11
After the reform and opening up, in the context of the party and the country vigorously promoting economic construction and developing a socialist market economy, China has continued to explore medical and health system reforms to expand the autonomy of medical institutions in response to the shortage of medical and health resources and the unequal distribution of resources.
-
Which pharmaceutical companies are making friends of time?
Time of Update: 2021-08-11
WuXi AppTec,Source: Company Annual ReportHengrui Pharmaceuticals, despite the fact that Hengrui’s sales staff account for the largest proportion, but Hengrui ranks first in R&D expenses.
